A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 43, Issue 6, 2004, Pages 637-643

  Yousef, Abdelmottaleb A ^a   Fryer, Christopher J H ^b   Chedid, Fares D ^c   Abbas, Adil A H ^a   Felimban, Sami K ^a   Khattab, Taha M ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b BC CHILDREN S HOSPITAL   (Canada)

^c TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

Childhood acute lymphoblastic leukaemia; Hospitalization; Prophylactic ciprofloxacin

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CEFTAZIDIME; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; NORFLOXACIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIOGUANINE; VANCOMYCIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILD HOSPITALIZATION; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DELAYED INTENSIFICATION; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 6944248887     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20065     Document Type: Article

References (44)

1. Henze G, Fengler R, Reiter A, et al. Impact of early Intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Hamatol Bluttransfus 1990;33:483-488.
2. Gustaffson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high risk patients: The Nordic experience of 2,648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151-1161.
3. Hann IM, Vora A, Richards SM, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC AL97 randomized trials. Leukemia 2000;14:356-363.
4. Gaynon PS, Bostrom BC, Hutchinson RJ, et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 2001;19:1916-1925.
5. Storring RA, Jameson B, McElwain TJ, et al. Oral nonabsorbable antibiotics prevent infections in acute lymphoblastic leukemia. Lancet 1977;2:837-884.
6. Karp JE, Merz WG, Hendrickson C, et al. Oral norfloxacin for the prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1-7.
7. Fenelon L. Strategies for prevention of infection in short-duration neutropenia. Infect Control Hosp Epidemiol 1988;19:590-592.
8. Cortellaro M, Confrancesco E, Pasargiklian I, et al. Ciprofloxacin for infection prophylaxis in granulocytopenic patients with acute leukemia. Haematologica 1990;75:541-545.
9. Orlandi E, Navarra A, Cruciani M, et al. Norfloxacin versus cotrimoxazole for infection prophylaxis in granulocytopenic patients with acute leukemia. A prospective randomized study. Haematologica 1990;75:296-298.
10. Klastersky J. Prevention of infection in neutropenic cancer patients. Curr Opin Oncol 1996;8:270-277.
11. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 1996;23:795-805.
12. Krupova Y, Novotny J, Sabo A, et al. Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteremia during antimicrobial prophylaxis: A case-control study. Int J Antimicrob Agents 1998;10:313-316.
13. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998;16:1179-1187.
14. Cruciani M. Antibacterial prophylaxis. Int J Antimicrob Agents 2000;16:123-125.
15. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001;12:1359-1368.
16. Nenova IS, Ananostev NH, Goranov SE, et al. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv) 2001;43:40-45.
17. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
18. Carratala J, Fernandez-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-560.
19. Zaidi Y, Hastings M, Murray J, et al. Quinolone resistance in neutropenic patients: The effect of prescribing policy in the UK and Pakistan. Clin Lab Haematol 2001;23:39-42.
20. Vanbelkum A, Goessens W, van der Schee C, et al. Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamycin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis 2001;7:862-871.
21. Chen DK, Mcgeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-239.
22. Little MA, Morland B, Chisholm J. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 2002;38:98-103.
23. Teinturier C, Hartman O, Lemerle J, et al. Prevention of gram-positive infections in patients treated with high dose chemotherapy and bone marrow transplantation: A randomized controlled trial of vancomycin. Pediatr Hematol Oncol 1995;12:73-77.
24. Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis 2003;22:1138-1142.
25. Cruciani M, Concia E, Navarra A, et al. Prophylactic cotrimoxazole versus norfloxacin in neutropenic children: Perspective randomised study. Infection 1989;17:65-69.
26. Patrick CC, Adair JR, Warner WC, Jr., et al. Safety of ciprofloxacin as a prophylactic agent for prevention of bacterial infections in pediatric bone marrow transplant (BMT) patients [Abstract LM 17]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology 1995; 329.
27. Mullen CA, Nair J, Sandesh S, et al. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. Bone Marrow Transplant 2000;25:59-65.
28. Schaad U, Salem MA, Anjard Y, et al. Use of fluoroquinolones in pediatrics; consensus report of the International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
29. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003;12:1128-1132.
30. Singh UK, Sinha RK, Prasad B, et al. Ciprofloxacin in children; is arthropathy a limitation? Indian J Pediatr 2000;67:386-387.
31. Yee CL, Duffy C, Gerbino PG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002;21:525-529.
32. Petrelli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin versus intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial. Med Pediatr Oncol 2000;34:87-91.
33. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126-134.
34. Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia: A randomized controlled trial. Cancer 2001;91:1563-1567.
35. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: A single-center, randomized, controlled trial in Argentina. Cancer 2003;97:1775-1780.
36. Bostrom B, Gaynon PS, Sather H, et al. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 1998;17:527a.
37. Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol 1999;457:593-605.
38. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukaemia. J Clin Oncol 1996;14:18-24.
39. Hurwitz CA, Siverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000;88:1964-1969.
40. Ingram J, Weitzman S, Greenberg ML, et al. Complications of indwelling venous access lines in pediatric haematology patients: A prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol 1991;13:130-136.
41. Wurzel CL, Halom K, Feldman JG. Infection rates of Broviac-Hickman catheters and implantable venous devices. Am J Dis Child 1988;142:536-540.
42. Abbas AA, Fryer CJ, Paltiel C, et al. Factors influencing central line infections in children with acute lymphoblastic leukaemia: Results of a single institutional study. Pediatr Blood Cancer 2004;42:325-331.
43. Mirro J, Jr., Rao BN, Kumar M, et al. A comparison of placement techniques and complications of externalised catheters and implantable port use in children with cancer. J Pediatr Surg 1990;25:120-124.
44. Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002;24:321-322.